These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2861888)

  • 1. Prediction of treatment response in schizophrenia: clinical use of neuroleptic blood levels.
    Tang SW
    Can J Psychiatry; 1985 Jun; 30(4):249-50. PubMed ID: 2861888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels.
    McCreadie RG; Robertson LJ; Wiles DH
    Br J Psychiatry; 1992 Jun; 160():793-9. PubMed ID: 1352165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia.
    Hogan TP; Awad AG; Eastwood MR
    Can J Psychiatry; 1985 Jun; 30(4):246-8. PubMed ID: 2861887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.
    Tune LE; Creese I; Depaulo JR; Slavney PR; Coyle JT; Snyder SH
    Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between plasma and red blood cell neuroleptic levels, oral dosage, and clinical parameters in a chronic schizophrenic population.
    Dunlop SR; Shea PA; Hendrie HC
    Biol Psychiatry; 1982 Aug; 17(8):929-36. PubMed ID: 6126231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system.
    Chouinard G; Annable L; Jones BD; Collu R
    Acta Psychiatr Scand; 1981 Nov; 64(5):353-62. PubMed ID: 6126066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
    Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics.
    Vital-Herne J; Gerbino L; Kay SR; Katz IR; Opler LA
    J Clin Psychiatry; 1986 Jul; 47(7):375-9. PubMed ID: 2873133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic-refractory patients and their drug plasma levels.
    Berrios GE
    Encephale; 1982; 8(4):465-85. PubMed ID: 6129961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radio receptor assay of serum neuroleptic levels in psychiatric patients.
    Krska J; Sampath G; Shah A; Soni SD
    Br J Psychiatry; 1986 Feb; 148():187-93. PubMed ID: 2870755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of relationship of neuroleptic dose and blood serum levels to neuropsychological performance on the LNNB in chronic schizophrenia.
    Puente AE; Tune L
    Int J Neurosci; 1996 Oct; 87(1-2):107-10. PubMed ID: 8913825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sulpiride: a neuroleptic agent of new generation with unique pharmacological qualities and rather wide range of clinical applications].
    Pawłowski L
    Psychiatr Pol; 1993; 27(2):199-205. PubMed ID: 8104350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problems in classification of schizophrenics as neuroleptic responders and nonresponders.
    Csernansky JG; Kaplan J; Hollister LE
    J Nerv Ment Dis; 1985 Jun; 173(6):325-31. PubMed ID: 2860202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacoepidemiology of treatment-refractory schizophrenia.
    Collins EJ; Hogan TP; Awad AG
    Can J Psychiatry; 1992 Apr; 37(3):192-5. PubMed ID: 1350502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.
    Orr MW; Knox JM; Allen R; Gelder MG; Grahame-Smith DG
    Br J Clin Pharmacol; 1981 Mar; 11(3):255-9. PubMed ID: 6111333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
    Young AS; Faraone SV; Brown WA
    J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood biogenic amines during clozapine treatment of early-onset schizophrenia.
    Schulz E; Fleischhaker C; Clement HW; Remschmidt H
    J Neural Transm (Vienna); 1997; 104(10):1077-89. PubMed ID: 9503259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of neuroleptic treatment on cortisol and 3-methoxy-4-hydroxyphenylethyl glycol levels in blood.
    Wik G
    J Endocrinol; 1995 Mar; 144(3):425-9. PubMed ID: 7738466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients.
    Lindenmayer JP; Smith D; Katz I
    J Clin Psychiatry; 1984 Mar; 45(3):117-9. PubMed ID: 6142035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.